Talquetamab: Mechanism of Action, Clinical, and Translational Science
Clinical and Translational Science · 2026-05 · 19 (5)
DOI: 10.1111/cts.70574 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, online erschienen am 13.05.2026. Verfasst von Yibo Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Johnson & Johnson, La Jolla, California, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Bispecific. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Talquetamab is a first‐in‐class, T‐cell–redirecting bispecific antibody targeting GPRC5D, a novel antigen highly expressed on malignant plasma cells with limited expression in normal tissues. Despite advances in treatment, multiple myeloma (MM) remains incurable, and talquetamab offers a promising therapeutic option for patients with relapsed/refractory MM. By binding to both GPRC5D on myeloma cells and CD3 on T cells, talquetamab induces T‐cell activation and subsequent lysis of GPRC5D‐expressing cells. The recommended subcutaneous (SC) dosing regimens of talquetamab monotherapy 0.4 mg/kg QW (preceded by step‐up doses of 0.01 and 0.06 mg/kg) or 0.8 mg/kg Q2W (preceded by step‐up doses of 0.01, 0.06, and 0.4 mg/kg) were selected based on the totality of safety, efficacy, pharmacokinetic, and pharmacodynamic data. Exposure‐response analyses for efficacy and safety further supported the dose selection. In clinical studies, talquetamab demonstrated robust and durable responses in heavily pretreated RRMM patients, with a favorable benefit–risk profile. Common adverse events included cytokine release syndrome, hematologic toxicities, oral adverse events (dysgeusia etc.), and infections, with hematological toxicities being the most common grade 3–4 events. During talquetamab treatment, 35.8% (130/363) of participants developed anti‐drug antibodies, including 18.2% (66/363) with neutralizing antibodies, across both recommended doses, and no clinically meaningful impact of immunogenicity on talquetamab pharmacokinetics, efficacy, or safety was observed. Talquetamab has received accelerated approval (US) and conditional marketing authorization (EU) with further ongoing investigation as monotherapy or in combination regimens across various MM treatment settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Johnson & Johnson, La Jolla, California, USA.
ORCID-Profile: Yibo Wang, Jue Gong, Jie Zhou, Dongfen Yuan, Jaszianne Tolbert, Nahor Haddish-Berhane
Zitieren
APA
Wang, Y., Gong, J., Au, N., Zhou, J., Yuan, D., Tolbert, J., Zhang, G., Vishwamitra, D., Zhang, J., Haddish-Berhane, N., & Singh, I. (2026). Talquetamab: Mechanism of Action, Clinical, and Translational Science. Clinical and Translational Science, 19(5). https://doi.org/10.1111/cts.70574
Vancouver
Wang Y, Gong J, Au N, Zhou J, Yuan D, Tolbert J, et al. Talquetamab: Mechanism of Action, Clinical, and Translational Science. Clinical and Translational Science. 2026;19(5). doi:10.1111/cts.70574
BibTeX
@article{Wang2026,
author = {Wang, Yibo and Gong, Jue and Au, Nicholas and Zhou, Jie and Yuan, Dongfen and Tolbert, Jaszianne and Zhang, Guoqiang and Vishwamitra, Deeksha and Zhang, Jenny and Haddish-Berhane, Nahor and Singh, Indrajeet},
title = {Talquetamab: Mechanism of Action, Clinical, and Translational Science},
journal = {Clinical and Translational Science},
year = {2026},
volume = {19},
number = {5},
doi = {10.1111/cts.70574}
}
EUVIMED